VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2020 | SWOG 1211: Phase II trial of RVD with elotuzumab for myeloma

Saad Usmani, MD, of the University of North Carolina School of Medicine, Chapel Hill, NC, discusses primary analysis of the randomized Phase II trial of bortezomib, lenalidomide and dexamethasone (RVD) with/without elotuzumab for newly diagnosed, high-risk multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter